Classification of ovarian carcinomas based on pathology and molecular genetics

Clinical and Translational Oncology

Volumn 12, Issue 12, 2010, Pages 783-787

  D'Angelo, Emanuela ^a   Prat, Jaime ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Carcinoma; Molecular genetics; Ovary; Pathology

Indexed keywords

ANIMALS; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARY; TUMOR MARKERS, BIOLOGICAL;

EID: 80255140140     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-010-0599-0     Document Type: Review

References (29)

1. Prat J (2004) Pathology of the ovary. Saunders, Philadelphia.
2. Lee KR, Tavassoli FA, Prat J et al (2003) Surface epithelial-stromal tumours (in Ch. 2: Tumours of the ovary and peritoneum). In: Tavassoli FA, Devilee P (eds) World Health Organization classification of tumours: pathology and genetics of tumours of the breast and female genital organs. IARC Press, Lyon, pp 117-145.
3. Gilks CB, Prat J (2009) Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol 40:1213-1223.
4. Singer G, Oldt R 3rd, Cohen Y et al (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95:484-486. (Pubitemid 36432423)
5. Singer G, Stohr R, Cope L et al (2005) Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis. Am J Surg Pathol 29:218-224. (Pubitemid 40170640)
6. Medeiros F, Muto MG, Lee Y et al (2006) The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 30:230-236. (Pubitemid 43740193)
7. Kindelberger DW, Lee Y, Miron A et al (2007) Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 31:161-169. (Pubitemid 46175016)
8. Leitao MM, Boyd J, Hummer A et al (2004) Clinicopathological analysis of early-stage sporadic ovarian carcinoma. Am J Surg Pathol 28:147-159. (Pubitemid 38124722)
9. Esteller M, Silva JM, Dominguez G et al (2000) Promoter hypermethylation is a cause of BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92:564-569. (Pubitemid 30212318)
10. Khalique L, Ayhan A, Weale ME et al (2007) Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. J Pathol 211:286-295. (Pubitemid 46172704)
11. Al-Hussaini M, Stockman A, Foster H, McCluggage WG (2005) WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 46:468.
12. duBois A, Luck HJ, Meier W et al (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320-1329.
13. Farmer H, McCabe N, Lord CJ et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921. (Pubitemid 40559006)
14. Gershenson DM, Sun CC, Lu KH et al (2006) Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 108:361- 368. (Pubitemid 44305678)
15. Malpica A, Deavers MT, Lu K et al (2004) Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 28:496-504. (Pubitemid 38436523)
16. Crispens MA, Bodurka D, Deavers M et al (2002) Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol 99:3-10. (Pubitemid 34075460)
17. Rodriguez IM, Prat J (2002) Mucinous tumors of the ovary. A clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas. Am J Surg Pathol 26:139-152. (Pubitemid 34127494)
18. Cuatrecasas M, Villanueva A, Matias-Guiu X, Prat J (1997) K-ras mutations in mucinous ovarian tumors. A clinicopathologic and molecular study of 95 cases. Cancer 79:1581-1586. (Pubitemid 27154791)
19. Park SY, Kim HS, Hong EK, Kim WH (2002) Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. Hum Pathol 33:1078- 1085.
20. Hess V, A'Hern R, Nasiri N et al (2004) Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 22:1040-1044. (Pubitemid 41095036)
21. Irving JA, Catasus L, Gallardo A et al (2005) Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the beta-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis. Hum Pathol 36:605-619. (Pubitemid 40922566)
22. Obata K, Morland SJ, Watson RH et al (1998) Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 58:2095-2097. (Pubitemid 28232892)
23. Palacios J, Gamallo C (1998) Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res 58:1344-1347. (Pubitemid 28193586)
24. Catasús L, Bussaglia E, Rodríguez IM et al (2004) Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum Pathol 35:1360-1368.
25. Sato N, Tsunoda H, Nishida M et al (2000) Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 60:7052-7056. (Pubitemid 32059184)
26. Komiyama S, Aoki D, Tominaga E et al (1999) Prognosis of Japanese patients with ovarian clear cell carcinoma associated with pelvic endometriosis: clinicopathologic evaluation. Gynecol Oncol 72:342-346. (Pubitemid 29118191)
27. Press JZ, de Luca A, Boyd N et al (2008) Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8:17.
28. Itamochi H, Kigawa J, Sugiyama T et al (2002) Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 100:281-287. (Pubitemid 34874791)
29. Nagai Y, Inamine M, Hirakawa M et al (2007) Postoperative whole abdominal radiotherapy in clear cell adenocarcinoma of the ovary. Gynecol Oncol 107:469-473. (Pubitemid 350160858)